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Abstract
Multimodal oncological strategies which combine chemotherapy or radio-
therapy with hyperthermia have a potential of improving the efficacy of the
non-surgical methods of cancer treatment. Hyperthermia engages the heat-
shock response mechanism (HSR), main component of which are heat-shock
proteins (HSP). Cancer cells have already partially activated HSR, thereby,
hyperthermia may be more toxic to them relative to normal cells. On the
other hand, HSR triggers thermotolerance, i.e. hyperthermia treated cells
show an impairment in their susceptibility to a subsequent heat-induced
stress. This poses questions about efficacy and optimal strategy of the anti-
cancer therapy combined with hyperthermia treatment.
To address these questions, we adapt our previous HSR model and pro-
pose its stochastic extension. We formalise the notion of a HSP-induced
thermotolerance. Next, we estimate the intensity and the duration of the
thermotolerance. Finally, we quantify the effect of a multimodal therapy
based on hyperthermia and a cytotoxic effect of bortezomib, a clinically ap-
proved proteasome inhibitor. Consequently, we propose an optimal strategy
for combining hyperthermia and proteasome inhibition modalities.
In summary, by a proof of concept mathematical analysis of HSR we are
able to support the common belief that the combination of cancer treatment
strategies increases therapy efficacy.
Key words: heat-shock response; thermotolerance; hyperthermia; pro-
teasome inhibitor; mass action kinetics
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Introduction
Most of the non-surgical methods of cancer treatment (e.g. chemotherapy
and radiotherapy) are based on the principle of putting some kind of stress
on cancer cells to induce their death. Unfortunately, in many cases the
above methods fail. The fact that heat-shock proteins (HSP) prevent apop-
tosis induced by different modalities of cancer treatment explains how these
proteins could limit the application of such anti-cancer therapies [1]. In or-
der to improve the efficacy of these treatments, some effort is focused on
the multimodal oncological strategies which usually combine treatment of
chemo- or radiotherapy with hyperthermia.
Heat-shock response in cancer treatment
HSP are a group of highly conserved proteins involved in many physiological
and pathological cellular processes. They are so called chaperones, as they
protect proteins from stress and help new and distorted proteins with folding
into their proper shape [2]. In principle, HSP synthesis increases under
stress conditions. Subsequently, upregulation of HSP increases cell survival
and stress-tolerance [3]. Elevated expression of different members of HSP
family has been detected in several cases of tumour (see, e.g., [4]). Despite
its importance, little is still known about how exactly HSP are involved
in different processes related to cancer development. In this work we are
interested in the heat-shock inducible isoform of heat-shock proteins 70 kDa
(Hsp70). For a sake of clarity, we will denote Hsp70 protein by HSP, and
use the former only if context might be unclear.
Hyperthermia is a therapeutic procedure used to raise the temperature
of a whole body or a region of the body affected by cancer. Body tissues
are, globally or locally, exposed to temperatures up to 45◦C [5]. Besides
characteristics specific to cell type, the effectiveness of hyperthermia depends
on the temperature achieved during the treatment, as well as on the length
of the treatment [5,6]. In general, moderate hyperthermia treatment, which
maintains temperatures in a moderate 40–42◦C range for about an hour,
does not damage most of normal tissues and has acceptable adverse effects [5,
7].
Currently, hyperthermia effectiveness is under study in clinical trials,
including combination with other cancer therapies [5, 7]. A synergistic in-
teraction of radiotherapy and hyperthermia as well as some cytotoxic drugs
and hyperthermia has already been confirmed in experimental studies [6].
In particular, Neznanov et al. [8] demonstrated, in vitro, that induction of
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heat-shock response (HSR) by hyperthermia enhances the efficacy of a pro-
teasome inhibitor called bortezomib — a FDA-approved drug for treatment
of a multiple myeloma and mantle cell lymphoma [9]. Basically, hyper-
thermia engages the HSR mechanism, main component of which are the
anti-apoptotic HSP. Cancer cells have already partially activated HSR be-
cause they are constitutively coping with higher level of misfolded protein
(mainly due to rapid rate of proliferation and specific intracellular condi-
tions of cancer cells). Therefore, in principle, sufficiently increased level of
misfolded proteins, as obtained by, e.g., hyperthermia, can not be matched
by cell’s HSR capacity and, in effect, such enhanced proteotoxic stress can
be more toxic to them relative to normal cells [8].
On the other hand, after a heat-shock, all cell types show an impair-
ment in their susceptibility to heat-induced cytotoxicity. This phenomenon,
known as thermotolerance, is triggered by HSR and it is, at least partially
based, on the upregulation of HSP [6]. Thermotolerance is, in principle,
reversible and persists for usually between 24 and 48 hours [5]. Due to
this phenomenon the applicability of the combined hyperthermia therapy
may be, counter-intuitively, initially limited. This naturally poses questions
about the efficacy and about an optimal strategy of the hyperthermia treat-
ment.
Our results
We formalise the notion of the HSP-induced thermotolerance i.e. the mem-
ory of the HSR system of the previous temperature perturbation, or, the
system desensitisation with respect to the second consecutive heat-shock.
Using mathematical modelling we compute the intensity and the duration
of the thermotolerance. Finally, we give a quantification of an effect of a
combined therapy of hyperthermia and an bortezomib-induced proteasome
inhibition. Based on that, we propose an optimal strategy for combination of
heat-shock and the inhibitor. In principle, our results support the common
belief that the combination of aforementioned cancer treatment strategies
increases therapy efficacy.
Model
The main purpose of this work is to contribute to the understanding of the
involvement of the HSR mechanism in multimodal cancer therapies. To
this end, we use a refined version of our previous deterministic model [10].
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Despite of its simplicity it provides a sound qualitative description of the
HSR mechanism.
This model captures dynamics of synthesis of HSP and its interactions
with key intracellular components of HSR, i.e.: HSP; the heat-shock factor
(HSF) and its trimer, which is a HSP transcription factor; HSP substrate —
mainly denatured, misfolded native proteins; HSP gene — heat-shock ele-
ment (HSE); and HSP mRNA. Fig. 1 depicts the overall model scheme, and
following reactions give the precise model structure:
HSP:HSF + S ↽−−⇀ HSP:S + HSF, (r1)
3 ·HSF −→ HSF3, (r2)
HSF3 + HSE −⇀↽ HSE:HSF3, (r3)
HSE:HSF3 −→ HSE:HSF3 + mRNA, (r4)
HSP + HSF3 −→ HSP:HSF + 2 ·HSF, (r5)
HSP + S ↽−−⇀ HSP:S, (r6)
HSP + HSF ↽−−⇀ HSP:HSF, (r7)
HSP −→ ∅, (r8)
HSP:S −→ HSP + P, (r9)
P
T−→ S, (r10)
mRNA −→ mRNA + HSP, (r11)
mRNA −→ ∅. (r12)
Four out of twelve reactions (Eqs r1–r12) are reversible, making it sixteen
reactions in total; T superscript over the reaction arrow denotes temperature
dependence. The proteins denaturation level dependence on temperature
is modelled by a power-exponential function, analogously to some of the
previous HSR mathematical models [10–13]. This type of functional relation
is based on an experimental calorimetric enthalpy data [14].
Deterministic mathematical model follows purely mass action kinetics
and it is represented by the first order ordinary differential equations (ODE).
Fig. 2 depicts behaviour of this model, which starts in the state of homeosta-
sis, i.e. in a steady state for T = 37◦C, in response to the immediate shift
of the temperature to T = 42◦C. Amounts of species are arbitrarily scaled,
each of them separately, to obtain values of a similar order of magnitude
for each species (denoted a.s.M). We calibrated this model with respect
to the HSE:HSF3 42
◦C experimental data [15] (Fig. S2 in the Supporting
Material).
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We additionally developed a stochastic counterpart of the deterministic
model, represented by chemical master equation (CME) or, equivalently,
continuous-time Markov process (CTMC), which we then analysed using the
probabilistic model checking technique (PMC). To ensure the feasibility of
this approach we used approximate PMC techniques, implemented recently
in the PRISM tool [16].
We found deterministic approach to be a valid approximation of stochas-
tic model, i.e., both variants presented very similar results with respect to
the stochastic mean. However, almost half of the modelled species exhibit
a significant noise level in the stochastic model. See Text S3 in the Support-
ing Material, Sec. 1 for details. Both deterministic and stochastic models
are additionally available in the Supporting Material, respectively, as a XML
File F1 in the SBML format [17], as well as a text File F2 in the PRISM
model format [16].
Results
Quantification of the thermotolerance phenomenon
Thermotolerance can be described as a desensitisation with respect to a con-
secutive heat-shock, compared to the response to the first heat-shock. In
other words, thermotolerance represents a memory of the system about the
first two, “on” and “off” temperature perturbations, leading to a decreased
response to the subsequent “on” perturbation. In case of the HSR system,
its memory is created by a propagating shift in species activity and the
feedback loop of the biochemical network (cf. Fig. 2).
Fig. 3 depicts the thermotolerance phenomena in the deterministic HSR
model for the immediate 42◦C heat-shock. Duration and strength of the
memory of the first temperature perturbation can be accurately tracked by
the activity of HSP, level of which is negatively correlated with the strength
of the response (cf. Fig. S4 in the Supporting Material).
In the stochastic model we introduce approximate perturbations as an
independent, k-level Poisson process (see Text S3 in the Supporting Mate-
rial, Sec. 3 for details). This allows to stay within the same mathemati-
cal model, i.e., CTMC, and seamlessly perform stochastic simulations and
model checking.
We define the notion of the HSP-induced thermotolerance during n-th
heat-shock (n > 1) as the desensitisation coefficient :
Dn = 1− RnR1 , (1)
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where n-th response Rn is defined as:
Rn = max
tn≤t<tn+1
{#S (t)−#S∗} , (2)
where #S∗ = Epi (#S) is a mean value of a species S amount in a steady
state pi; tn is a n-th heat-shock start time (we assume tn+1 = ∞ if not
specified otherwise); and the first response, by assumption, satisfies R1 > 0.
Such response measure represents the toxicity of the heat-shock: the higher
the response the more likely the cell will die. For the deterministic model
the species amount is simply a scaled value of ODE variable, corresponding
to the mean value of a stochastic process random variable.
Fig. 4 depicts value of the desensitisation coefficient D2 for the substrate
species, with respect to the time gap between heat-shocks. After the first
heat-shock, at the time gap of the approximated memory loss, i.e. at ca.
400 min, system is very close to the homeostasis steady state (cf. Fig. S1 in
the Supporting Material, t ≈ ∆t1 + 400 ≈ 470 min).
In the stochastic model we may observe a non-zero (slightly positive)
level of mean D2, after the thermotolerance effect has vanished. More im-
portantly, the stochastic variant presents a constantly high standard devia-
tion of the desensitisation intensity: ca. 20% of its expected maximum level
(which is observed for the very short time gap between heat shocks). These
results, as well as the overall difference with respect to the deterministic
model, may be attributed to the stochastic noise and the fact that we take
a maximum amount of substrate in Eq. 2 to measure its toxic influence, not
the mean value.
Hyperthermia in multimodal oncological strategies
It has been hypothesised that because hyperthermia engages HSR mecha-
nism and because capacity of this mechanism is limited, especially in cancer
cells, hyperthermia enhances the toxicity induced by a second modality of
cancer treatment [8]. This synergistic effect of hyperthermia and other can-
cer therapies can be attributed to the much higher accumulation of dena-
tured proteins (substrate), which are deadly for cell. In our modelling ap-
proach we investigate, by means of the presented mathematical HSR model,
the temperature dependence of the heat-shock response in combination with
bortezomib-induced inhibition of proteasome.
In our intracellular-level model we assume that hyperthermia treatment
is represented by a heat-shock with an immediate temperature shift, as
presented in previous section. In order to incorporate into the model the
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inhibitory effect of bortezomib, we limit the HSP-assisted degradation of
denatured proteins (Eq. r9) and degradation of HSP itself (Eq. r8). More
precisely, we linearly scale both reaction rate constants k, i.e., we set (1−I)·k,
for I ∈ [0, 1], where I represents current inhibition level (when no drug is
administrated I = 0 whereas in case of maximum inhibition I = I100).
We used bortezomib pharmacodynamics as modelled by Sung & Si-
mon [18]. Namely, the inhibition level linearly raises up to its maximum
level at t100=60 min, after which it decays with a half-life t50 = 12 · t100, i.e.:
I (t) = I100 ·
{
t
t100
for t ≤ t100
e−kI(t−t100) for t > t100
, (3)
where kI = ln (2)/t50 . The maximum inhibition level I100 directly corre-
sponds to the drug dose. For a maximum tolerated bortezomib dose, I100
is equal to ca. 65%, while for some of the next-generation proteasome in-
hibitors, such as carfilzomib or ONX-0912, both of which are in clinical
development, it was possible to reach over 80% proteasome inhibition in
blood (with consecutive-day dosing schedules) [9].
Fig. 5 depicts activity of substrate and HSP:substrate complex, with
respect to an unimodal proteasome inhibition treatment for a range of its
maximum levels I100, as well as a unimodal hyperthermia treatment and
combined 65% maximum inhibition treatment for a range of moderate hy-
perthermia temperatures. Recall that activity peak of a cytotoxic substrate
defines level of heat-shock response R1 (Eq. 2). The higher the response is
the more effective is the therapy in terms of indicating a higher probability
of death of a cancer cell.
The bortezomib-based proteasome inhibition and hyperthermia induce
a very similar total number of denatured proteins (see Fig. 5). However, in
case of proteasome inhibition vast majority of these proteins is being secured
in HSP:substrate complexes on the fly. This is due to the gradual increase
of bortezomib inhibition effect, which is not fast enough with respect to
a rate at which new HSP molecules are synthesised. The immediate heating
has a much better effect in terms of substrate cytotoxicity. Furthermore,
when both therapies are applied simultaneously levels of both substrate and
HSP:substrate complex indeed are higher than in case of an application of
only one of the treatment modalities. HSR capacity, as represented by an
analogous R1 coefficient for HSP:substrate complex (cf. Eq. 2), is much
closer to saturation plateau in case of the 65% peak inhibition level than
without inhibition (see Fig. 5). Hence, increase of the temperature has a bet-
ter effect in the combined treatment, in the sense of a deadly accumulation
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of free substrate molecules.
Fig. 6 depicts this synergistic effect in a continuous scale of both the
temperature and the maximum inhibition level of bortezomib. A mono-
tone increase in response with respect to both modalities can be observed
regardless of the heat-shock application time (see Fig. S5 in the Support-
ing Material). We found that multimodal toxicity response increases by
over 40% with respect to a unimodal hyperthermia response for a maximum
inhibition level equal to reported 65%, up to over 80% increase for a theoret-
ical maximum of 100% of proteasome inhibition. Moreover, we established
t∗1 ≈ 38 min as an optimal time to start hyperthermia treatment in combi-
nation with 65% bortezomib inhibition (see Fig. 6). Interestingly, this is not
in agreement with a maximum area under the bortezomib inhibition curve
(AUC), a common pharmacokinetic efficacy measure. For the heat-shock
duration ∆t1 = 71 min, AUC maximum is reached at t1 ≈ 56 min (see
Fig. S6 in the Supporting Material). Timing of heat-shock in the optimal
multimodal treatment strategy t∗1 can be intuitively explained by the follow-
ing observations (cf. Fig. 5). Firstly, time required for denatured proteins
to peak after the beginning of a heat-shock is roughly the same as the time
gap between t∗1 and t100 (22 min). Secondly, at t∗1 the inhibition itself has
still a relatively low impact. This way, inhibition peak coincides with the
period of maximum temperature-induced toxicity, at which HSR mechanism
is the most occupied, thus effecting in the optimal synergistic toxicity.
Conclusions and Discussion
We formalised and quantified the notion of thermotolerance induced by
the HSP-based mechanism of heat-shock response. Although we found a de-
terministic approach to be a valid approximation of the stochastic HSR
model, the latter variant presented a high level of intrinsic noise. In conse-
quence, we observe a significant level of intrinsic thermotolerance intensity
which can be highly increased by the heat-shock accompanied by a high
reduction of variability. We would like to emphasise that in this analysis we
demonstrated feasibility and practical potential of the probabilistic model
checking technique, more specifically its lesser known approximate variant.
Next, by mathematical modelling of HSR we were able to support the
common belief that the combined cancer treatment strategies can more
effectively increase cytotoxicity of denatured proteins in cancer cells than
unimodal strategies. Moreover, we presented an optimal starting time for
a moderate hyperthermia treatment in combination with a proteasome in-
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hibitor application. This is an example of how mechanistic modelling can
surpass pharmakokinetic measures of optimal drug efficacy, such as AUC
(which basically is an optimisation only with respect to system’s input).
We suggest that the synergistic effect of hyperthermia and other cancer
treatment modalities (like chemo- and radiotherapies) is caused by increased
accumulation of denatured proteins, i.e., heat and drug-sensitive proteins or
heat and radiation-sensitive proteins. This results in bigger demand for
heat-shock proteins and higher selective barrier for cells.
Our model-based analysis proves successful in reproducing experimen-
tal knowledge of key aspects of hyperthermia treatment, and as such offers
reasonable framework for studying its connections with heat-shock response.
However, all of the kinetic models of molecular biological systems and means
of their analysis are incomplete due to constraints under which these mod-
els are formulated. In this regard, we would like to point out that this is
a proof of concept model-based analysis and there are many issues to address
within this work. For instance, we omitted the investigation of the day-based
strategies of multimodal treatment. This is because we found that in our
HSR model the single cell level thermotolerance duration (ca. 6.5h) is much
shorter than the bortezomib decay (12h half-life), thus, making the latter
a determining factor for a standard, daily dosing schedule. The inconsistency
between reported (24-48h) and simulated duration of thermotolerance can
be primarily attributed to the fact that thermotolerance, in general, is most
likely not only induced by the HSP upregulation (cf. [19]). Secondly, this
inconsistency may also be attributed to the simplistic single cell modelling of
the immediate temperature shift, disregarding spatial heat distribution and
the preheating period as in, e.g., the whole-body hyperthermia (cf. [5]). In
this regard, to provide solid, quantitative results, our model requires more
extensive calibration with respect to experimental data, including the be-
haviour for varying temperatures (cf. [10, 20]). Nevertheless, undoubtedly,
our analysis gives a valuable mathematical framework for model-based un-
derstanding of hyperthermia treatment strategies, such as these combining
hyperthermia with very promising therapeutic proteasome inhibitors.
Methods
Model was defined using the SBML-shorthand notation [21], and auto-
matically generated in the SBML format [17]. The ODE model was nu-
merically solved using the MathSBML package of the Mathematica soft-
ware [22]. The corresponding stochastic version of this model, represented by
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CME or, equivalently, CTMC (cf. [23]), was analysed using the PMC tech-
nique. To ensure the feasibility of this approach we have used approximate
PMC techniques (APMC), implemented recently in the PRISM tool [16].
Consequently, all stochastic simulations and the confidence interval-based
APMC were done using PRISM. To create the PRISM model, we used
a prototype SBML translator which generates model specification in the
PRISM language. Minor adjustments, such as factorisation of parameters
or accounting for mass conservation laws were done manually.
For means of modelling frameworks comparison and stochastic noise
quantification (see Text S3 in the Supporting Material, Sec. 1) as well as
for thermotolerance quantification (see Fig. 4) we used PRISM rewards to
describe first and second moments of, respectively, species variables as well
as one minus desensitisation coefficient (see Eq. 1). Text S3 in the Support-
ing Material, Sec. 2 describes in detail the unbiased estimators and their
symmetric confidence intervals for mean, variance, variance-to-mean ratio,
and for standard deviation of both species and desensitisation coefficient
random variables.
To stay within CTMC framework and, consequently, to seamlessly per-
form stochastic simulations or model checking, we introduced approximate
stochastic perturbation events based on n-counting Poisson processes. Pre-
cision of a single perturbation event, measured as a standard deviation,
is proportional by square root to the number of counting levels n and in-
verse linearly proportional to the expected time of occurrence of this event.
The approximate stochastic perturbation strategy for on and off heat-shock
events was encoded manually in PRISM language, according to the scheme
presented in Text S3 in the Supporting Material, Sec. 3.
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Figure Legends
Figure 1.
Scheme of the HSR model. Squares represent species, including complexes,
and dots represent reactions, with substrates and products denoted respec-
tively by incoming and outgoing arrows. On the left side of the scheme, the
denaturation of native proteins P and refolding or degradation of denatured
proteins S (substrate) moderated by the HSP chaperones. On the right side,
the adaptive HSP production loop, stimulated by HSF, which trimerise and
initiate HSE transcription and HSP mRNA translation (dotted arrow). As
a negative feedback, HSP molecules promote HSF trimers dissociation and
inhibit single HSF molecules by direct binding. The loop is closed by the
inflowing substrate which forces out inhibited HSF out of the complex with
HSP.
Figure 2.
Numerical simulations of the HSR ODE model for a constant 42◦C heating
strategy. Simulation starts at a 37◦C steady state.The upper plot depicts
HSP response to the temperature-stimulated inflow of denatured proteins S
(substrate). Free substrate is instantaneously bound into a HSP:S complex.
Insufficient amount of free HSP causes its extraction from the HSP:HSF
complex, forming an initiative response of the cell. Released in exchange
HSF induces adaptive production of HSP molecules to complement its de-
ficiency as indicated by accumulation of S, with peak at ca. 25 min. After
over 120 min the excess of upregulated HSP is used to inhibit HSF activity.
System completely stabilises after ca. 650 min (Fig. S1 in the Supporting
Material) with most of constantly inflowing S secured in the HSP:S com-
plexes. The lower plot depicts the adaptive HSP production, stimulated by
HSF. HSF trimerises and initiate HSE transcription to mRNA, followed by
further translation to HSP, as visible by the shifted activity of subsequent
components.
Figure 3.
Thermotolerance in the heat-shock response: the substrate activity (solid)
during the two consecutive immediate heat-shocks (dotted) of 5◦C over the
homeostatis level of 37◦C. The intensity of intoxication resulting from the
amount of substrate (filled area) depends on the time gap between heat-
shocks. Interestingly, activity of the substrate in the second shock can be
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even higher than activity in the first shock, as shown for the time gap of
240 min. This is due to a temporary deficit of HSP (see. Fig. S4 in the
Supporting Material for details).
Figure 4.
The desensitisation coefficient D2 for the substrate in the ODE model (black
line) and its mean and standard deviation in CTMC, plotted against the
time gap between end of the first heat-shock and the beginning of the sec-
ond heat-shock. Duration of both heat-shocks ∆tn (n = 1, 2) is equal to
71 min. Memory of the first heat-shock is lost when the desensitisation co-
efficient value stabilises around 0, which is approximately at 400 min for both
mathematical models. Mean (yellow line) and standard deviation (orange
line) of D2 was calculated at selected time points (dots). Both estimators
have a confidence interval with 95% confidence level. In case of the mean
value the confidence interval width is less than 5 · 10−3, whilst for the stan-
dard deviation the confidence interval is depicted as a strip. Estimators
were calculated using APMC with 104 and 5 · 104 independent simulation
samples for the first and the second moment respectively (see Text S3 in the
Supporting Material, Sec. 2 for details).
Figure 5.
The heat-shock response with respect to different temperatures and to differ-
ent inhibition levels, applied separately (unimodal treatments) and simulta-
neously (combined treatment). The upper left plot depicts ODE trajectory
of the substrate (solid lines) and the HSP:substrate complex (dashed lines),
upon a 71 min heat-shock induced at 38 min for T = 37, 38 . . . , 42◦C. The
upper right plot depicts the same trajectories for bortezomib maximum in-
hibition levels I100 = 0, 20, . . . , 100%. In the similar manner the bottom left
plot presents an effect of combining both therapies for varying T and fixed
I100 = 65%. Finally, the substrate toxic response coefficient R1 (Eq. 2) and
the analogous coefficient for HSP:S, measuring HSR capacity, are depicted in
the bottom right plot with respect to T ∈ [37, 47], i.e. a continuous temper-
ature range, broadened for a context. For a comparisonR1 coefficient curves
are presented for both a unimodal hyperthermia treatment (thin lines) and
a treatment combined with I100 = 65% (thick lines).
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Figure 6.
Contour plot of the heat-shock response level R1 with respect to a heat-
shock temperature (vertical axis) and with respect to a maximum level of
proteasome inhibition for heat-shock applied at t1 = 38 min (left plot), or
with respect to time of heat-shock application at maximum inhibition of
I100 = 65% (right plot). Heat-shock takes ∆t1 = 71 min. Level of R1
(Eq. 2), denoted on the plot by colours from blue (the weakest) to red (the
strongest), measures the toxicity of the combined therapy. Dashed vertical
line at each plot denotes conditions for the other plot. Choice for maximum
inhibition level I100 was driven by data reported in literature (see text for
details), whereas choice for heat-shock time was based on maximisation of
the multimodal strategy response (cf. right plot).
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Supporting Material index
Figure S1: Stability of the HSR ODE model.
Figure S2: The HSE:HSF3 fit to the experimental data.
Text S3: Stochastic modelling of HSR
Figure S4: The substrate and HSP response to the two consecutive imme-
diate heat-shocks.
Figure S5: Contour plots of the heat-shock response level for multiple
equally-distributed heat-shock application times.
Figure S6: Area under the bortezomib inhibition curve (AUC) versus heat-
shock application time.
Additional Files index
File F1: XML file in the SBML format containing deterministic model of
HSR.
File F2: Text file in the PRISM model format containing stochastic model
of HSR.
